Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY.
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY.
J Vasc Surg. 2023 Sep;78(3):593-601.e4. doi: 10.1016/j.jvs.2023.04.042. Epub 2023 May 19.
Open repair of acute complicated type B aortic dissection (ACTBAD), required when endovascular repair is not possible, is historically considered high-risk. We analyze our experience with this high-risk cohort compared with the standard cohort.
We identified consecutive patients undergoing descending thoracic or thoracoabdominal aortic aneurysm (TAAA) repair from 1997 to 2021. Patients with ACTBAD were compared with those having surgery for other reasons. Logistic regression was used to identify associations with major adverse events (MAEs). Five-year survival and competing risk of reintervention were calculated.
Of 926 patients, 75 (8.1%) had ACTBAD. Indications included rupture (25/75), malperfusion (11/75), rapid expansion (26/75), recurrent pain (12/75), large aneurysm (5/75), and uncontrolled hypertension (1/75). The incidence of MAEs was similar (13.3% [10/75] vs 13.7% [117/851], P = .99). Operative mortality was 5.3% (4/75) vs 4.8% (41/851) (P = .99). Complications included tracheostomy (8%, 6/75), spinal cord ischemia (4%, 3/75), and new dialysis (2.7%, 2/75). Renal impairment, urgent/emergent operation, forced expiratory volume in 1 second ≤50%, and malperfusion were associated with MAEs, but not ACTBAD (odds ratio: 0.48, 95% confidence interval [CI]: [0.20-1.16], P = .1). At 5 and 10 years, there was no difference in survival (65.8% [95% CI: 54.6-79.2] vs 71.3% [95% CI: 67.9-74.9], P = .42, and 47.3% [95% CI: 34.5-64.7] vs 53.7% [95% CI: 49.3-58.4], P = .29, respectively) or 10-year reintervention (12.5% [95% CI: 4.3-25.3] vs 7.1% [95% CI: 4.7-10.1], P = .17, respectively).
In an experienced center, open repair of ACTBAD can be performed with low rates of operative mortality and morbidity. Outcomes similar to elective repair are achievable even in high-risk patients with ACTBAD. In patients unsuitable for endovascular repair, transfer to a high-volume center experienced in open repair should be considered.
急性复杂型 B 型主动脉夹层(ACTBAD)的开放修复在血管内修复不可行时是必需的,历史上被认为是高风险的。我们分析了与标准队列相比,我们在这一高风险队列中的经验。
我们确定了 1997 年至 2021 年期间接受降胸主动脉或胸腹主动脉瘤(TAAA)修复的连续患者。将 ACTBAD 患者与因其他原因接受手术的患者进行比较。使用逻辑回归来确定与主要不良事件(MAE)相关的因素。计算了 5 年生存率和再干预的竞争风险。
在 926 名患者中,75 名(8.1%)患有 ACTBAD。适应症包括破裂(25/75)、灌注不良(11/75)、快速扩张(26/75)、复发性疼痛(12/75)、大动脉瘤(5/75)和未控制的高血压(1/75)。MAE 的发生率相似(13.3%[10/75]与 13.7%[117/851],P=0.99)。手术死亡率为 5.3%(4/75)与 4.8%(41/851)(P=0.99)。并发症包括气管造口术(8%,6/75)、脊髓缺血(4%,3/75)和新透析(2.7%,2/75)。肾功能不全、紧急/急诊手术、用力呼气量 1 秒≤50%和灌注不良与 MAE 相关,但与 ACTBAD 无关(比值比:0.48,95%置信区间[CI]:[0.20-1.16],P=0.1)。在 5 年和 10 年时,生存率没有差异(65.8%[95%CI:54.6-79.2]与 71.3%[95%CI:67.9-74.9],P=0.42,和 47.3%[95%CI:34.5-64.7]与 53.7%[95%CI:49.3-58.4],P=0.29,分别)或 10 年再干预(12.5%[95%CI:4.3-25.3]与 7.1%[95%CI:4.7-10.1],P=0.17,分别)。
在经验丰富的中心,ACTBAD 的开放修复可实现低手术死亡率和发病率。即使在高危 ACTBAD 患者中,也可实现与择期修复相似的结果。对于不适合血管内修复的患者,应考虑将其转至在开放修复方面经验丰富的大容量中心。